Computerised counting of tumour infiltrating lymphocytes in 90 breast cancer specimens

被引:46
作者
Marsigliante, S
Biscozzo, L
Marra, A
Nicolardi, G
Leo, G
Lobreglio, GB
Storelli, C
机构
[1] Univ Lecce, Dipartimento Biol, Lab Fisiol Gen, I-73100 Lecce, Italy
[2] Osped Multizonale V Fazzi, Lab Anal Clin, Lecce, Italy
[3] Univ Lecce, Dipartimento Biol, Lab Anat Umana, I-73100 Lecce, Italy
[4] Osped Multizonale V Fazzi, Lab Ematol & Immunol, Lecce, Italy
关键词
breast cancer; lymphocytes; CD;
D O I
10.1016/S0304-3835(98)00379-6
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Tumour infiltrating lymphocytes (TILs) implicated in immunologic cytotoxicity were evaluated by immunohistochemistry and digitally counted in serial Sections from 90 breast cancers in order to assess their number, the relationships between them and to tumour histology. CD3(+), CD4(+) CD8(+), CD20(+), CD25(+) and CD56(+) lymphocytes were found in 58 (64.4%), 52 (57.7%), 50 (55.5%), 22 (24.4%), 11 (12.2%) and 21 (23.3%) tumours, respectively. There was no difference in the number of TILs between pure infiltrating ductal (NOS) and non-ductal carcinomas, and no relationship between TILs and histological grades was found, CD3(+)TILs directly correlated to age, while lymph node negative patients had tumours infiltrated by fewer CD4(+)TILs with respect to lymph node positive patients. In 25/98 patients, randomly chosen, the status of peripheral blood lymphocytes was evaluated but no differences with respect to the status found in healthy blood donors was obtained; nonetheless while in some patients CD8(+)TILs outnumbered CD4(+)TILs in situ, the CD4/CD8 ratio was normal in their peripheral blood. The results show a considerable diversity of TISs among breast tumours, their lack of relationship with the status of the peripheral blood cells, and their potential important relationship with age (CD3(+)) and lymph node status (CD4(+)). (C) 1999 Elsevier Science Ireland Ltd. All rights reserved.
引用
收藏
页码:33 / 41
页数:9
相关论文
共 24 条
[1]   RELATIVE SIGNIFICANCE OF PROGNOSTIC FACTORS IN BREAST CARCINOMA [J].
ALDERSON, MR ;
STAUNTON, MD ;
HAMLIN, I .
BRITISH JOURNAL OF CANCER, 1971, 25 (04) :646-+
[2]   PHASE-I EVALUATION OF RECOMBINANT INTERLEUKIN-2 IN PATIENTS WITH ADVANCED MALIGNANT DISEASE [J].
ATKINS, MB ;
GOULD, JA ;
ALLEGRETTA, M ;
LI, JJ ;
DEMPSEY, RA ;
RUDDERS, RA ;
PARKINSON, DR ;
REICHLIN, S ;
MIER, JW .
JOURNAL OF CLINICAL ONCOLOGY, 1986, 4 (09) :1380-1391
[3]  
BHAN AK, 1983, J NATL CANCER I, V71, P507
[4]  
BILIK R, 1989, CANCER IMMUNOL IMMUN, V28, P143
[5]   HISTOLOGICAL GRADING AND PROGNOSIS IN BREAST CANCER - A STUDY OF 1409 CASES OF WHICH 359 HAVE BEEN FOLLOWED FOR 15 YEARS [J].
BLOOM, HJG ;
RICHARDSON, WW .
BRITISH JOURNAL OF CANCER, 1957, 11 (03) :359-&
[6]  
CHIN Y, 1992, ANTICANCER RES, V12, P1463
[7]   LYMPHOCYTES INFILTRATING HUMAN-BREAST CANCERS LACK K-CELL ACTIVITY AND SHOW LOW-LEVELS OF NK-CELL ACTIVITY [J].
EREMIN, O ;
COOMBS, RRA ;
ASHBY, J .
BRITISH JOURNAL OF CANCER, 1981, 44 (02) :166-176
[8]   Phase I study of subcutaneously administered interleukin-2 in combination with interferon alfa-2a in patients with advanced cancer [J].
Gause, BL ;
Sznol, M ;
Kopp, WC ;
Janik, JE ;
Smith, JW ;
Steis, RG ;
Urba, WJ ;
Sharfman, W ;
Fenton, RG ;
Creekmore, SP ;
Holmlund, J ;
Conlon, KC ;
VanderMolen, LA ;
Longo, DL .
JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (08) :2234-2241
[9]  
GHARIB M, 1993, B CANCER, V80, P659
[10]  
HANK JA, 1988, CANCER RES, V48, P1965